Metabolic profile association with white matter hyperintensity in patients with mild cognitive impairment.
The study found significant associations between certain metabolites and white matter hyperintensity in mild cognitive impairment, but the clinical implications remain unclear.
Where it sits
this study against the rest of the vasopressin corpusSummary and findings
This study investigated the association between metabolite profiles and white matter hyperintensity (WMH) in patients with mild cognitive impairment (MCI). A total of 189 subjects were included, with 112 classified as MCI. The study reported various odds ratios (OR) for metabolites correlated with WMH.
Abstract
Brain vasculopathy, including cerebral white matter hyperintensity (WMH), is highly associated with mild cognitive impairment (MCI) and Alzheimer's disease (AD) pathology. Metabolite levels provide clues to illuminate the mechanism of WMH in MCI. Therefore, the current study investigated the association between metabolite profile and WMH in MCI. Metabolite profiles and WMH data of MCI patients with three consecutive years of follow-up were retrospectively extracted from the ADNI database. Multivariate logistic regression and mixed model regression adjusted for age, gender, education, and ADAS-Cog13 were used to evaluate the association between metabolite levels and WMH. A total number of 189 subjects were included in this study, allocated into three groups of healthy individuals (n = 67), mild cognitive impairment (n = 112), and AD (n = 10). Based on the multivariate logistic regression, methionine, deoxycholic acid, trimethylamine N-oxide, glutamic acid, and alanine, palmitoylethanolamide, and arachidonic acid positively correlated with WMH (OR:4.014 [95% CI: 1.329-12.128]; OR: 1.272 [95% CI: 1.076-1.504]; OR: 1.839 [95% CI: 1.007-1.390]; OR: 8.474 [95% CI: 2.730-26.300]; OR: 3.532 [95% CI: 1.544-8.076]; OR: 2.486 [95% CI: 1.152-5.364]; OR:2.110 [95% CI: 1.003-4.440], respectively), while tyrosine, proline, histidine, and beta-aminobutyric acid negatively correlated with WMH (OR:0.287 [95% CI:0.092-0.894]; OR:0.381 [95% CI:0.162-0.894]; OR:0.240 [95% CI:0.059-0.982]; OR: 0.598 [95% CI: 0.382-0.939], respectively). The association of metabolite levels with WMH in the MCI group is complex. One of the suggested mechanisms is amino acid overconsumption in the MCI group, resulting in decreasing their detected level in the serum while accumulation of their metabolites in the brain increases the risk of WMH.
Background
This paper addresses the relationship between metabolite levels and white matter hyperintensity (WMH) in patients with mild cognitive impairment (MCI), a condition often associated with Alzheimer's disease. Previous research has indicated that brain vasculopathy, including WMH, is linked to cognitive decline. Understanding the metabolite profiles could provide insights into the mechanisms underlying WMH in MCI, which is critical for future research.
Methods
The study utilized a retrospective analysis of metabolite profiles and WMH data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. A total of 189 subjects were included, divided into three groups: healthy individuals (n=67), MCI (n=112), and Alzheimer's disease (n=10). Multivariate logistic regression and mixed model regression were employed to evaluate the associations, adjusting for age, gender, education, and ADAS-Cog13.
Results
The primary endpoint indicated that several metabolites were significantly associated with WMH in the MCI group. For example, glutamic acid had an odds ratio of 8.474 [95% CI: 2.730-26.300], indicating a strong positive correlation with WMH. Other metabolites such as methionine and deoxycholic acid also showed positive correlations, while tyrosine and histidine were negatively correlated with WMH.
Interpretation
The findings suggest a complex relationship between metabolite levels and WMH in MCI, with some metabolites showing strong positive correlations. However, the clinical significance of these associations is uncertain, particularly given the small sample size for the Alzheimer's group and the retrospective nature of the study. These results should be interpreted with caution, as they may not directly translate to clinical practice without further validation.
Key findings
- OR: 4.014 [95% CI: 1.329-12.128] for methionine positively correlated with WMH.
- OR: 1.272 [95% CI: 1.076-1.504] for deoxycholic acid positively correlated with WMH.
- OR: 8.474 [95% CI: 2.730-26.300] for glutamic acid positively correlated with WMH.
- OR: 0.287 [95% CI: 0.092-0.894] for tyrosine negatively correlated with WMH.
- OR: 0.240 [95% CI: 0.059-0.982] for histidine negatively correlated with WMH.
Limitations
- Retrospective analysis from ADNI database.
- Small sample size for Alzheimer's disease group (n=10).
- Potential confounding factors not fully controlled.
- Short follow-up duration not specified.